Preoperative chemotherapy for operable breast cancer

Cancer Treat Res. 2000;103:137-55. doi: 10.1007/978-1-4757-3147-7_7.

Abstract

In the NSABP B-18 study, it was demonstrated that, in patients with operable breast cancer, the administration of preoperative and postoperative chemotherapy resulted in similar DFS and overall survival outcomes. In addition, preoperative chemotherapy resulted in high clinical response rates but in low rates of pathologic response in the breast. Axillary nodal downstaging was convincingly demonstrated. In addition, it was also demonstrated in B-18, as well as in other studies, that there was an increase in breast conservation rates after the administration of preoperative chemotherapy. The role of preoperative chemotherapy for operable breast cancer continues to be evaluated in randomized trials, which have the potential of providing further insight into the biologic and clinical questions relative to the timing of adjuvant therapy for the disease.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / surgery
  • Chemotherapy, Adjuvant*
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Female
  • Forecasting
  • Humans
  • Mammography / methods
  • Mastectomy*
  • Mastectomy, Segmental
  • Multicenter Studies as Topic
  • Postmenopause
  • Premedication*
  • Premenopause
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Surgical Instruments
  • Survival Rate
  • Treatment Outcome

Substances

  • Biomarkers, Tumor